135062-02-1 | 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$12.00	$8.00
100mg	98%	in stock	$13.00	$9.00
250mg	98%	in stock	$18.00	$12.00
1g	98%	in stock	$29.00	$20.00
10g	98%	in stock	$265.00	$186.00
25g	98%	in stock	$510.00	$357.00

Description

• Catalog Number: AB50518
• Chemical Name: 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid
• CAS Number: 135062-02-1
• Molecular Formula: C27H36N2O4
• Molecular Weight: 452.5857
• MDL Number: MFCD00906179
• SMILES: CCOc1cc(ccc1C(=O)O)CC(=O)N[C@H](c1ccccc1N1CCCCC1)CC(C)C
• NSC Number: 759893

Computed Properties

• Complexity: 619
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 10
• XLogP3: 5.2

Literature

• Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays.

  Toxicology in vitro : an international journal published in association with BIBRA 20151225

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.

  Basic & clinical pharmacology & toxicology 20130401

• In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.

  Drug development and industrial pharmacy 20121101

• Validated stability-indicating spectrofluorimetric method with enhanced sensitivity for determination of repaglinide in tablets.

  Journal of fluorescence 20121101

• Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.

  Diabetes & vascular disease research 20121001

• NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.

  British journal of clinical pharmacology 20120901

• Analysis of repaglinide enantiomers in pharmaceutical formulations by capillary electrophoresis using 2,6-di-o-methyl-β-cyclodextrin as a chiral selector.

  Journal of chromatographic science 20120901

• Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20120901

• Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.

  Drug metabolism and disposition: the biological fate of chemicals 20120701

• Synthesis, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]thiazol-2-ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B inhibitors.

  European journal of medicinal chemistry 20120701

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Association of muscarinic M₃ receptors and Kir6.1 with caveolae in human detrusor muscle.

  European journal of pharmacology 20120515

• Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514

• Adulteration of herbal antidiabetic products with undeclared pharmaceuticals: a case series in Hong Kong.

  British journal of clinical pharmacology 20120501

• Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits.

  Molecular and cellular biochemistry 20120501

• Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

  Drug metabolism and disposition: the biological fate of chemicals 20120501

• KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients.

  Clinical and experimental pharmacology & physiology 20120501

• Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.

  Clinical pharmacology and therapeutics 20120501

• [Hypoglycemia - frequency, causes, induced costs].

  Deutsche medizinische Wochenschrift (1946) 20120501

• The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport.

  Molecular pharmaceutics 20120402

• Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.

  The Journal of pharmacology and experimental therapeutics 20120401

• Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.

  Naunyn-Schmiedeberg's archives of pharmacology 20120301

• Role of the amino-terminal transmembrane domain of sulfonylurea receptor SUR2B for coupling to K(IR)6.2, ligand binding, and oligomerization.

  Naunyn-Schmiedeberg's archives of pharmacology 20120301

• In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.

  Pharmaceutical research 20120201

• Variations in tissue selectivity amongst insulin secretagogues: a systematic review.

  Diabetes, obesity & metabolism 20120201

• Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.

  Journal of pharmacokinetics and pharmacodynamics 20120201

• Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China.

  Biomedical and environmental sciences : BES 20120201

• Repaglinide: a review of its use in type 2 diabetes mellitus.

  Drugs 20120122

• Design and optimization of a stomach-specific drug delivery system of repaglinide: application of simplex lattice design.

  Pharmaceutical development and technology 20120101

• From evidence assessments to coverage decisions?: the case example of glinides in Germany.

  Health policy (Amsterdam, Netherlands) 20120101

• Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.

  Journal of drug delivery 20120101

• Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

  Journal of clinical pharmacology 20120101

• Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production.

  Cardiovascular diabetology 20120101

• Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress.

  Experimental diabetes research 20120101

• In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation.

  International journal of nanomedicine 20120101

• Editorial preface to the first issue of 2012.

  Journal of cardiovascular disease research 20120101

• Athero-protective actions of two oral antidiabetic drugs: Suppression of inflammation and oxidative stress.

  Journal of cardiovascular disease research 20120101

• Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbits.

  Journal of cardiovascular disease research 20120101

• Chronic kidney disease, severe arterial and arteriolar sclerosis and kidney neoplasia: on the spectrum of kidney involvement in MELAS syndrome.

  BMC nephrology 20120101

• Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.

  Die Pharmazie 20120101

• The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.

  Pharmacology 20120101

• Preparation, characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion.

  Chemical & pharmaceutical bulletin 20120101

• Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide.

  Experimental diabetes research 20120101

• Performance scores in general practice: a comparison between the clinical versus medication-based approach to identify target populations.

  PloS one 20120101

• Uncovering undetected hypoglycemic events.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• [Prevalence of diabetes mellitus in geriatric patients in nursing homes of Cádiz. Diagerca study].

  Revista espanola de geriatria y gerontologia 20120101

• Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.

  ISRN endocrinology 20120101

• Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.

  Swiss medical weekly 20120101

• Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.

  Expert opinion on pharmacotherapy 20111201

• Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.

  Clinical therapeutics 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20111101

• The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

  International journal of clinical practice 20111101

• Hypoglycemia revisited in the acute care setting.

  Yonsei medical journal 20111101

• Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs).

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111009

• Kinetic characterization of rat hepatic uptake of 16 actively transported drugs.

  Drug metabolism and disposition: the biological fate of chemicals 20111001

• Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.

  Drug metabolism and disposition: the biological fate of chemicals 20111001

• Effect of nicotinamide mononucleotide on insulin secretion and gene expressions of PDX-1 and FoxO1 in RIN-m5f cells.

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20111001

• The Effects of Glyburide on Apoptosis and Endoplasmic Reticulum Stress in INS-1 Cells in a Glucolipotoxic Condition.

  Diabetes & metabolism journal 20111001

• Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes.

  Diabetes, obesity & metabolism 20110901

• Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20110901

• Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.

  Drug metabolism and disposition: the biological fate of chemicals 20110901

• The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.

  Clinical pharmacokinetics 20110901

• Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.

  European heart journal 20110801

• NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.

  Clinical and experimental pharmacology & physiology 20110801

• Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.

  Nanotechnology 20110708

• Expression of sulfonylurea receptors in rat taste buds.

  Acta histochemica 20110701

• Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.

  European journal of clinical pharmacology 20110701

• Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.

  Journal of pharmaceutical sciences 20110601

• In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.

  Journal of pharmaceutical sciences 20110601

• Hydrogels based on interpenetrating network of chitosan and polyvinyl pyrrolidone for pH-sensitive delivery of repaglinide.

  Current drug discovery technologies 20110601

• Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.

  Diabetes care 20110601

• Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.

  Annales d'endocrinologie 20110601

• Primary language, income and the intensification of anti-glycemic medications in managed care: the (TRIAD) study.

  Journal of general internal medicine 20110501

• A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20110501

• Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.

  Drug metabolism and disposition: the biological fate of chemicals 20110501

• [Clinical parameters for molecular testing of Maturity Onset Diabetes of the Young (MODY)].

  Deutsche medizinische Wochenschrift (1946) 20110501

• Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry.

  Analytical and bioanalytical chemistry 20110401

• Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.

  Clinical pharmacology and therapeutics 20110401

• Diabetes treatment and cardiovascular safety.

  Diabetes care 20110401

• Cohort study of pioglitazone and cancer incidence in patients with diabetes.

  Diabetes care 20110401

• A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.

  Journal of medicinal chemistry 20110324

• Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes.

  European journal of endocrinology 20110301

• Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.

  Clinical pharmacology and therapeutics 20110301

• Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201

• Validated spectrophotometric methods for determination of some oral hypoglycemic drugs.

  Drug discoveries & therapeutics 20110201

• Aqueous Extract from Hibiscus sabdariffa Linnaeus Ameliorate Diabetic Nephropathy via Regulating Oxidative Status and Akt/Bad/14-3-3γ in an Experimental Animal Model.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Small molecule inhibitors of the human papillomavirus E1-E2 interaction.

  Current topics in microbiology and immunology 20110101

• Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules.

  Journal of biomedicine & biotechnology 20110101

• Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.

  Diabetes technology & therapeutics 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006.

  Cardiovascular diabetology 20110101

• Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.

  Current drug metabolism 20110101

• Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.

  Chinese medical journal 20110101

• 2-Deoxy-D-glucose reverses the Indian red scorpion venom-induced cardiopulmonary abnormalities in anesthetized rats.

  Indian journal of experimental biology 20110101

• Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress.

  Biologics : targets & therapy 20110101

• Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Hypersensitivity to repaglinide.

  Journal of investigational allergology & clinical immunology 20110101

• Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report.

  Journal of medical case reports 20110101

• Precursor B-cell acute lymphoblastic leukemia presenting as obstructive jaundice: a case report.

  Journal of medical case reports 20110101

• Diabetes and Ramadan: an update on use of glycemic therapies during fasting.

  Annals of Saudi medicine 20110101

• Extensive Spinal Cord Injury following Staphylococcus aureus Septicemia and Meningitis.

  Case reports in neurology 20110101

• New onset diabetes after transplantation (NODAT): an overview.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Small molecule inhibitors of human papillomavirus protein - protein interactions.

  The open virology journal 20110101

• Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.

  Journal of nutrition and metabolism 20110101

• Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

  PloS one 20110101

• A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients.

  Health and quality of life outcomes 20110101

• Medicinal chemistry of novel anti-diabetic drugs.

  The open medicinal chemistry journal 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Ramadan and diabetes: As-Saum (The fasting).

  Indian journal of endocrinology and metabolism 20110101

• [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101

• Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.

  Open medicine : a peer-reviewed, independent, open-access journal 20110101

• Novel anti-inflammatory effects of repaglinide in rodent models of inflammation.

  Pharmacology 20110101

• Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.

  Particle and fibre toxicology 20110101

• Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone.

  Diabetology & metabolic syndrome 20110101

• Management of diabetes across the course of disease: minimizing obesity-associated complications.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors.

  International journal of molecular sciences 20110101

• Delusional infestation in a patient with renal failure, metabolic syndrome, and chronic cerebrovascular disease treated with aripiprazole: a case report.

  Case reports in medicine 20110101

• Multiple myeloma and diabetes.

  ISRN endocrinology 20110101

• Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay.

  ISRN pharmaceutics 20110101

• Formulation and evaluation of transdermal patch of repaglinide.

  ISRN pharmaceutics 20110101

• Carbamazepine-induced acute generalized exanthematous pustulosis: a case report.

  The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20110101

• Angelica archengelica extract induced perturbation of rat skin and tight junctional protein (ZO-1) of HaCaT cells.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes.

  Clinical medicine insights. Endocrinology and diabetes 20110101

• Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study.

  Diabetes care 20101201

• Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.

  European journal of clinical pharmacology 20101201

• Smoking and risk for diabetes incidence and mortality in Korean men and women.

  Diabetes care 20101201

• Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study.

  Diabetes care 20101201

• Electrochemical characterization of repaglinide and its determination in human plasma using liquid chromatography with dual-channel coulometric detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101201

• Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement.

  Diabetes care 20101201

• Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

  Diabetes care 20101201

• Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism.

  British journal of clinical pharmacology 20101201

• Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201

• Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

  Diabetes care 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• SLCO1B1 polymorphism and oral antidiabetic drugs.

  Basic & clinical pharmacology & toxicology 20101001

• [Electrocardiographic score: application in exercise test for the assessment of ischemic preconditioning].

  Arquivos brasileiros de cardiologia 20101001

• Organic solvent-free approach to single step fabrication of Eudragit nanoparticles using Labrasol.

  Die Pharmazie 20101001

• Sitagliptin-induced hemolysis.

  Indian journal of pharmacology 20101001

• [Sulfonylureas dosage: from therapeutic monitoring to differential diagnosis of hyperinsulinism].

  Revue medicale de Liege 20100901

• In vitro characterization and invivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles.

  International journal of pharmaceutics 20100830

• The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.

  Diabetes care 20100801

• Recommendations for management of diabetes during Ramadan: update 2010.

  Diabetes care 20100801

• Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.

  Therapeutic delivery 20100701

• Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil.

  Acta diabetologica 20100601

• Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

  International journal of clinical practice 20100601

• Neuropathy, retinopathy, and glucose-lowering treatments.

  Diabetes care 20100601

• IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.

  Acta pharmacologica Sinica 20100601

• Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide.

  Journal of clinical pharmacology 20100501

• The nasty surprise of a complex drug-drug interaction.

  Drug discovery today 20100501

• Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.

  Diabetes research and clinical practice 20100401

• Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database.

  Pharmacy world & science : PWS 20100401

• Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.

  The Annals of pharmacotherapy 20100401

• Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

  Annals of the rheumatic diseases 20100401

• A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.

  Acta pharmacologica Sinica 20100401

• KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.

  Clinical pharmacology and therapeutics 20100301

• Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin.

  Journal of Korean medical science 20100301

• Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.

  Archives of pharmacal research 20100301

• Opening of ATP-sensitive potassium channel by insulin in the brain-induced insulin secretion in Wistar rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100201

• Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.

  Journal of clinical pharmacology 20100201

• Diabetes under control: Understanding oral antidiabetic agents.

  The American journal of nursing 20100201

• Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm.

  Journal of clinical pharmacy and therapeutics 20100201

• Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits.

  Bioscience trends 20100201

• Aspects of insulin treatment.

  Diabetes care 20100101

• Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method.

  Current drug delivery 20100101

• Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus.

  Diabetes technology & therapeutics 20100101

• Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract.

  Nutrition & metabolism 20100101

• Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients.

  Mediators of inflammation 20100101

• Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial.

  BMJ (Clinical research ed.) 20100101

• Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.

  Vascular health and risk management 20100101

• Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.

  Current chemical genomics 20100101

• Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial.

  BMJ (Clinical research ed.) 20100101

• CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.

  Pharmacology 20100101

• Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society.

  Diabetology & metabolic syndrome 20100101

• Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects.

  PloS one 20100101

• The well-being and treatment satisfaction of diabetic patients in primary care.

  Health and quality of life outcomes 20100101

• The tsim tsoum approaches for prevention of cardiovascular disease.

  Cardiology research and practice 20100101

• Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study.

  Health and quality of life outcomes 20100101

• Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors.

  Cardiovascular diabetology 20100101

• Development of Spectrofluorimetric and HPLC Methods for In vitro Analysis of Repaglinide.

  Indian journal of pharmaceutical sciences 20100101

• Characteristics of coronary artery disease in symptomatic type 2 diabetic patients: evaluation with CT angiography.

  Cardiovascular diabetology 20100101

• Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus.

  Nutrition & metabolism 20100101

• Carbamazepine-loaded porous microspheres for short-term sustained drug delivery.

  Journal of young pharmacists : JYP 20100101

• In vitro Evaluation of Novel Sustained Release Microspheres of Glipizide Prepared by the Emulsion Solvent Diffusion-Evaporation Method.

  Journal of young pharmacists : JYP 20100101

• Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Impact of rosiglitazone meta-analysis on use of glucose-lowering medications.

  Open medicine : a peer-reviewed, independent, open-access journal 20100101

• Design and optimization of floating drug delivery system of acyclovir.

  Indian journal of pharmaceutical sciences 20100101

• Nateglinide versus repaglinide for type 2 diabetes mellitus in China.

  Acta diabetologica 20091201

• Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans.

  Diabetes care 20091201

• CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.

  Drug metabolism and disposition: the biological fate of chemicals 20091201

• Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement.

  International journal of clinical practice 20091101

• Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.

  Diabetes care 20091101

• Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.

  Diabetes care 20091101

• Metabolomics applied to diabetes research: moving from information to knowledge.

  Diabetes 20091101

• Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.

  Diabetes, obesity & metabolism 20091001

• Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.

  Diabetes 20091001

• Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.

  Diabetes care 20091001

• Accuracy of Veterans Affairs databases for diagnoses of chronic diseases.

  Preventing chronic disease 20091001

• Impact of OATP transporters on pharmacokinetics.

  British journal of pharmacology 20091001

• Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.

  Diabetes, obesity & metabolism 20090901

• The role of transporters in the pharmacokinetics of orally administered drugs.

  Pharmaceutical research 20090901

• Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

  Pharmacogenomics 20090901

• Global variation in CYP2C8-CYP2C9 functional haplotypes.

  The pharmacogenomics journal 20090801

• Thiazolidinediones and cardiovascular risk - a question of balance.

  Current cardiology reviews 20090801

• Change in glucometer settings as a cause of sudden deterioration of glycemic control in type 2 diabetes.

  Diabetes technology & therapeutics 20090701

• Successful treatment of repaglinide-induced hypoglycemia with octreotide.

  The American journal of emergency medicine 20090701

• Metformin/Repaglinide (PrandiMet) for type 2 diabetes.

  The Medical letter on drugs and therapeutics 20090601

• Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide.

  Experimental lung research 20090601

• Determination of antihyperglycemic drugs in nanomolar concentration levels by micellar electrokinetic chromatography with non-ionic surfactant.

  Journal of chromatography. A 20090515

• Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen.

  Clinics (Sao Paulo, Brazil) 20090501

• Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

  Journal of medicinal chemistry 20090409

• Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.

  Journal of proteome research 20090401

• Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1.

  The Journal of biological chemistry 20090313

• Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.

  Acta diabetologica 20090301

• Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.

  Acta diabetologica 20090301

• Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.

  Current medical research and opinion 20090301

• Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.

  Journal of diabetes 20090301

• Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

  Diabetes care 20090101

• Standards of medical care in diabetes--2009.

  Diabetes care 20090101

• The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.

  Journal of endocrinological investigation 20090101

• Postprandial hyperglycemia as an etiological factor in vascular failure.

  Cardiovascular diabetology 20090101

• Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

  Drug safety 20090101

• DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol.

  BMC endocrine disorders 20090101

• Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose.

  Nutrition journal 20090101

• Co-solvent solubilization of some poorly-soluble antidiabetic drugs.

  Pharmaceutical development and technology 20090101

• Acute heart failure in a patient with metabolic syndrome and diabetes mellitus: clinical evidence for direct positive influence of antidiabetic therapy on left ventricular function.

  Congestive heart failure (Greenwich, Conn.) 20090101

• A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

  Cardiovascular diabetology 20090101

• Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration.

  Bratislavske lekarske listy 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Diabetic nephropathy.

  Diabetology & metabolic syndrome 20090101

• Post-transplant diabetes mellitus.

  Diabetology & metabolic syndrome 20090101

• Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

  BMJ (Clinical research ed.) 20090101

• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

  BMJ (Clinical research ed.) 20090101

• Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations.

  Experimental diabetes research 20090101

• Effect of Ramadan fasting on anthropometric parameters and food consumption in 276 type 2 diabetic obese women.

  International journal of diabetes in developing countries 20090101

• Repaglinide induced acute hepototoxicity.

  JNMA; journal of the Nepal Medical Association 20090101

• Role of potassium channels in stretch-promoted atrial natriuretic factor secretion.

  Journal of the American Society of Hypertension : JASH 20090101

• pH-Sensitive Mebeverine Microspheres for Colon Delivery.

  Indian journal of pharmaceutical sciences 20090101

• Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Fixed combination of repaglinide and metformin in the management of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column.

  Journal of chromatography. A 20081226

• Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.

  Diabetes, obesity & metabolism 20081201

• The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

  British journal of clinical pharmacology 20081201

• Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.

  Vascular health and risk management 20081201

• Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.

  Vascular health and risk management 20081201

• Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

  Diabetes care 20081101

• Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

  Pharmacogenetics and genomics 20081101

• Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

  Journal of medicinal chemistry 20081009

• Weight change in diabetes and glycemic and blood pressure control.

  Diabetes care 20081001

• Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin.

  Chemical biology & drug design 20081001

• International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations.

  Diabetic medicine : a journal of the British Diabetic Association 20081001

• Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.

  Clinical pharmacology and therapeutics 20081001

• The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.

  Clinical pharmacology and therapeutics 20080901

• Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids.

  Clinical pharmacology and therapeutics 20080901

• Glycemic control in diabetes: a tale of three studies.

  Diabetes care 20080901

• Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism.

  The pharmacogenomics journal 20080801

• Synthesis of hydantoin analogues of (2S,3R,4S)-4-hydroxyisoleucine with insulinotropic properties.

  Bioorganic & medicinal chemistry letters 20080801

• Approaches to treatment of type 2 diabetes.

  Diabetes care 20080801

• Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.

  Acta pharmacologica Sinica 20080801

• Novel de novo mutation in sulfonylurea receptor 1 presenting as hyperinsulinism in infancy followed by overt diabetes in early adolescence.

  Diabetes 20080701

• Drugs for type 2 diabetes.

  Treatment guidelines from the Medical Letter 20080701

• Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.

  Diabetes 20080601

• Interaction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in Alloxan Induced Diabetic Mice.

  Evidence-based complementary and alternative medicine : eCAM 20080601

• Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.

  The AAPS journal 20080601

• Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.

  Pharmaceutical research 20080501

• Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.

  European journal of endocrinology 20080501

• Severe hypoglycemia from clarithromycin-repaglinide drug interaction.

  Pharmacotherapy 20080501

• Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401

• [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20080401

• Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.

  Acta diabetologica 20080301

• Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

  Journal of clinical pharmacology 20080301

• Hypoglycaemia in Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20080301

• Spermicidal activity of sulfonylureas and meglitinide analogues: role of intrasperm Ca2+ elevation.

  The Journal of pharmacy and pharmacology 20080301

• Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets.

  Clinical therapeutics 20080301

• Postprandial hyperglycemia: are all sulfonylureas created equal?

  The American journal of cardiology 20080215

• Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.

  European journal of clinical pharmacology 20080201

• Ameliorating effects of sulfonylurea drugs on insulin resistance in Otsuka long-evans Tokushima Fatty rats.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20080201

• Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes.

  Diabetes research and clinical practice 20080101

• Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

  European journal of endocrinology 20080101

• Electrochemical determination of the antidiabetic drug repaglinide.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20080101

• Radioiodinated naphthylalanine derivatives targeting pancreatic beta cells in normal and nonobese diabetic mice.

  Experimental diabetes research 20080101

• The relationship between type of drug therapy and blood glucose self-monitoring test strips claimed by beneficiaries of the Seniors' Pharmacare Program in Nova Scotia, Canada.

  BMC health services research 20080101

• A comparative study of first-derivative spectrophotometry and column high-performance liquid chromatography applied to the determination of repaglinide in tablets and for dissolution testing.

  Journal of AOAC International 20080101

• Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin : randomized, single-blind, three-period crossover study in healthy subjects.

  Clinical drug investigation 20080101

• Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.

  PloS one 20080101

• Diabetes: glycaemic control in type 2.

  BMJ clinical evidence 20080101

• Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice.

  International journal of clinical practice 20071201

• A review of nateglinide in the management of patients with type 2 diabetes.

  Vascular health and risk management 20071201

• Optimizing combination treatment in the management of type 2 diabetes.

  Vascular health and risk management 20071001

• A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

  Vascular health and risk management 20071001

• Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.

  Annals of internal medicine 20070918

• Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901

• Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.

  The Journal of pharmacology and experimental therapeutics 20070801

• Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury.

  The Journal of clinical investigation 20070801

• Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes.

  Current medical research and opinion 20070801

• Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process.

  AAPS PharmSciTech 20070720

• A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.

  Diabetic medicine : a journal of the British Diabetic Association 20070701

• Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.

  Diabetes, obesity & metabolism 20070701

• Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615

• Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.

  International journal of clinical practice. Supplement 20070601

• Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.

  Diabetes, obesity & metabolism 20070501

• Meglitinide analogues for type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20070418

• Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies.

  Journal of pharmaceutical and biomedical analysis 20070411

• New oral agents for type 2 diabetes.

  Clinical medicine (London, England) 20070401

• Porous carrier based floating granular delivery system of repaglinide.

  Drug development and industrial pharmacy 20070401

• [Chronic kidney disease and antidiabetic treatment].

  Revue medicale suisse 20070307

• A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.

  Diabetes research and clinical practice 20070201

• Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels.

  Vascular pharmacology 20070201

• Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

  Coronary artery disease 20070201

• Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion.

  Diabetic medicine : a journal of the British Diabetic Association 20070201

• Use of repaglinide on a pregnant woman during embryogenesis.

  Diabetes, obesity & metabolism 20070101

• Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.

  Clinical pharmacokinetics 20070101

• Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues.

  Health and quality of life outcomes 20070101

• Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.

  Cardiovascular diabetology 20070101

• Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101

• Rapid identification of P-glycoprotein substrates and inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20061201

• Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment.

  Acta diabetologica 20061201

• Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.

  British journal of clinical pharmacology 20061101

• Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay.

  Biomedical chromatography : BMC 20061001

• Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women.

  Diabetes care 20061001

• Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.

  Diabetologia 20060901

• Cyclosporine A increases plasma concentrations and effects of repaglinide.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060901

• Pharmacological interaction between cyclosporine a and repaglinide. Is it clinically relevant?

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060901

• Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial.

  Diabetes care 20060801

• Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801

• Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics.

  Neurology 20060725

• A novel calcium silicate based microspheres of repaglinide: in vivo investigations.

  Journal of controlled release : official journal of the Controlled Release Society 20060628

• Ionization, lipophilicity and solubility properties of repaglinide.

  Journal of pharmaceutical and biomedical analysis 20060607

• Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS.

  Journal of pharmaceutical and biomedical analysis 20060503

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Peroxisome proliferator-activated receptor gamma agonists in renal disease.

  European journal of endocrinology 20060501

• Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.

  Acta diabetologica 20060501

• Transporters as a determinant of drug clearance and tissue distribution.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060401

• Repaglinide in the management of new-onset diabetes mellitus after renal transplantation.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060401

• Meglitinide analogues: a review of clinical data focused on recent trials.

  Diabetes & metabolism 20060401

• Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.

  European journal of clinical pharmacology 20060301

• Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia.

  International journal of clinical practice 20060301

• Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.

  Clinical pharmacology and therapeutics 20060301

• An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.

  The Medical journal of Malaysia 20060301

• Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.

  Diabetic medicine : a journal of the British Diabetic Association 20060201

• Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.

  Drug metabolism and disposition: the biological fate of chemicals 20060101

• The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.

  British journal of clinical pharmacology 20060101

• Pioglitazone: a review of its use in type 2 diabetes mellitus.

  Drugs 20060101

• Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives.

  Current medicinal chemistry 20060101

• Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance.

  Cardiovascular diabetology 20060101

• Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus).

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101

• Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin.

  Diabetes/metabolism research and reviews 20060101

• Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations.

  Journal of AOAC International 20060101

• Spotlight on pioglitazone in type 2 diabetes mellitus.

  Treatments in endocrinology 20060101

• Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.

  Health and quality of life outcomes 20060101

• Type 2 diabetes mellitus: a review of pharmacological treatment.

  Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria 20060101

• Basic Management of Diabetes Mellitus: Practical guidelines.

  The Libyan journal of medicine 20060101

• Modification of cardiac oxidative stress in alloxan-induced diabetic rabbits with repaglinide treatment.

  Life sciences 20051205

• Oral agents in managing diabetes mellitus in children and adolescents.

  Pediatric clinics of North America 20051201

• [Synthesis and insulinotropic activity of 2-benzylidenesuccinic acid derivatives].

  Yao xue xue bao = Acta pharmaceutica Sinica 20051201

• Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization.

  Journal of controlled release : official journal of the Controlled Release Society 20051003

• Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20051001

• Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

  Basic & clinical pharmacology & toxicology 20051001

• Cyclosporine markedly raises the plasma concentrations of repaglinide.

  Clinical pharmacology and therapeutics 20051001

• [Recent oral antidiabetic therapy].

  Revue medicale de Bruxelles 20050901

• Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals.

  Pharmacological research 20050801

• Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.

  British journal of clinical pharmacology 20050801

• Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin.

  Diabetes care 20050701

• Mild, reversible pancytopenia induced by rosiglitazone.

  Diabetes care 20050601

• Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits: effect of repaglinide.

  Acta diabetologica 20050601

• Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

  Clinical pharmacology and therapeutics 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.

  Diabetes & metabolism 20050601

• Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.

  Diabetes care 20050501

• Effects of repaglinide on oxidative stress in tissues of diabetic rabbits.

  Diabetes research and clinical practice 20050501

• In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors.

  Pharmaceutical research 20050401

• Cholestatic hepatitis associated with repaglinide.

  Diabetes care 20050301

• [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20050301

• Oral antihyperglycemic agents and renal disease: new agents, new concepts.

  Journal of the American Society of Nephrology : JASN 20050301

• Repaglinide administration improves brachial reactivity in type 2 diabetic patients.

  Diabetes care 20050201

• Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.

  British journal of pharmacology 20050201

• Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.

  The Israel Medical Association journal : IMAJ 20050201

• Sulfonylurea induced beta-cell apoptosis in cultured human islets.

  The Journal of clinical endocrinology and metabolism 20050101

• Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.

  Metabolism: clinical and experimental 20050101

• Examination of 209 drugs for inhibition of cytochrome P450 2C8.

  Journal of clinical pharmacology 20050101

• Islet adaptation to insulin resistance: mechanisms and implications for intervention.

  Diabetes, obesity & metabolism 20050101

• Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Drug interactions of clinical importance with antihyperglycaemic agents: an update.

  Drug safety 20050101

• Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

  Clinical pharmacokinetics 20050101

• Postprandial glucose regulation: new data and new implications.

  Clinical therapeutics 20050101

• Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes.

  Core evidence 20050101

• The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium.

  Diabetes 20041201

• Accuracy of continuous nocturnal glucose screening after 48 and 72 hours in type 2 diabetes patients on combined oral and insulin therapy.

  Diabetes & metabolism 20041201

• Acute hepatotoxicity caused by repaglinide.

  Annals of internal medicine 20041116

• Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041105

• Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.

  Diabetic medicine : a journal of the British Diabetic Association 20041101

• Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent.

  Bioorganic & medicinal chemistry letters 20041018

• Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

  British journal of clinical pharmacology 20041001

• The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.

  Diabetic medicine : a journal of the British Diabetic Association 20041001

• Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.

  Biochemical pharmacology 20040901

• Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.

  The Journal of clinical endocrinology and metabolism 20040901

• Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.

  Pharmacological research 20040801

• Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.

  Current medical research and opinion 20040801

• Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.

  Health news (Waltham, Mass.) 20040801

• Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

  Circulation 20040713

• Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET).

  Nuclear medicine and biology 20040701

• Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20040701

• Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

  Diabetes care 20040601

• Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.

  Diabetes, nutrition & metabolism 20040601

• Evidence for hypothalamic K+(ATP) channels in the modulation of glucose homeostasis.

  European journal of pharmacology 20040510

• The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.

  Endocrine research 20040501

• Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts.

  Naunyn-Schmiedeberg's archives of pharmacology 20040401

• The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.

  British journal of clinical pharmacology 20040401

• Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.

  European journal of clinical pharmacology 20040401

• Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes.

  Diabetes research and clinical practice 20040401

• Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20040401

• Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.

  Archives of internal medicine 20040308

• The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20040301

• Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.

  Diabetes research and clinical practice 20040201

• Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.

  Diabetes & metabolism 20040201

• The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.

  The Journal of clinical endocrinology and metabolism 20040101

• Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.

  Clinical pharmacokinetics 20040101

• Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

  PharmacoEconomics 20040101

• Mitiglinide: KAD 1229, S 21403.

  Drugs in R&D 20040101

• Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.

  Diabetes/metabolism research and reviews 20040101

• Interactions between grapefruit juice and cardiovascular drugs.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101

• Continuous glucose monitoring: physiologic and pathophysiologic significance.

  Romanian journal of internal medicine = Revue roumaine de medecine interne 20040101

• The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients.

  Acta medica Indonesiana 20040101

• [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].

  MMW Fortschritte der Medizin 20031218

• Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.

  Diabetes care 20031201

• Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.

  Diabetes care 20031201

• Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20031201

• Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.

  British journal of cancer 20031117

• [Type 2 diabetes mellitus pathogenesis: new therapeutic managements?].

  La Revue de medecine interne 20031101

• Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.

  Diabetic medicine : a journal of the British Diabetic Association 20031101

• Neuronal calcium sensor proteins are direct targets of the insulinotropic agent repaglinide.

  The Biochemical journal 20031001

• Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.

  Clinical pharmacology and therapeutics 20031001

• Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20031001

• CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.

  British journal of clinical pharmacology 20030901

• Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030901

• Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions.

  Diabetes & metabolism 20030901

• Impurity profile study of repaglinide.

  Journal of pharmaceutical and biomedical analysis 20030714

• Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

  Diabetes care 20030701

• [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?

  Drug and therapeutics bulletin 20030701

• A comparison of costs for four oral antidiabetic regimens within a managed care population.

  Managed care interface 20030701

• Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.

  Diabetes research and clinical practice 20030601

• The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20030601

• Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.

  Journal of clinical pharmacology 20030601

• [Meglitinide analogs: new insulinotropic agents for the treatment of non-insulin dependent diabetes].

  Revue medicale de Bruxelles 20030601

• [Differences between oral antidiabetics].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20030320

• Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.

  Diabetes care 20030301

• Metformin-induced hemolytic anemia in a patient with glucose-6- phosphate dehydrogenase deficiency.

  Diabetes care 20030301

• Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.

  Diabetologia 20030301

• The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.

  Diabetologia 20030301

• The mechanisms underlying the unique pharmacodynamics of nateglinide.

  Diabetologia 20030301

• Rationale and options for combination therapy in the treatment of Type 2 diabetes.

  Diabetologia 20030301

• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.

  Diabetologia 20030301

• Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.

  Clinical therapeutics 20030201

• The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.

  Diabetes research and clinical practice 20030101

• Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.

  Journal of clinical pharmacology 20030101

• Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions.

  Journal of diabetes and its complications 20030101

• Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

  PharmacoEconomics 20030101

• [Drug safety. Notes regarding drug surveillance].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101

• Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.

  Treatments in endocrinology 20030101

• Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations.

  European journal of pharmacology 20021205

• No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.

  Journal of clinical pharmacology 20021201

• Sulfonylurea stimulation of insulin secretion.

  Diabetes 20021201

• Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes.

  Diabetes, nutrition & metabolism 20021201

• Repaglinide at a cellular level.

  Diabetes, nutrition & metabolism 20021201

• Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.

  Diabetes, nutrition & metabolism 20021201

• The impact of prandial glucose regulation in practice.

  Diabetes, nutrition & metabolism 20021201

• Repaglinide in combination therapy.

  Diabetes, nutrition & metabolism 20021201

• High-frequency insulin pulsatility and type 2 diabetes: from physiology and pathophysiology to clinical pharmacology.

  Diabetes & metabolism 20021201

• Hypoglycemia probably due to accidental intake of repaglinide.

  Chang Gung medical journal 20021101

• Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.

  Diabetes research and clinical practice 20021001

• Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.

  Diabetes care 20021001

• Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.

  Diabetes 20020901

• [Structures and mechanisms for non SU insulin secretagogues].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Repaglinide (NN-623)].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor.

  Analytical biochemistry 20020815

• Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.

  Diabetes care 20020801

• Response to Schmitz. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.

  Diabetes care 20020801

• [Differential type 2 diabetes therapy based on pathophysiological aspects].

  Therapeutische Umschau. Revue therapeutique 20020801

• Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis.

  European journal of endocrinology 20020701

• Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.

  European journal of pharmacology 20020503

• [Glinides and glitazones in diabetes treatment. Are they really effective?].

  MMW Fortschritte der Medizin 20020502

• Current oral agents for type 2 diabetes. Many options, but which to choose when?

  Postgraduate medicine 20020501

• Insulinotropic meglitinide analogues.

  Lancet (London, England) 20020406

• Subclinical type 1 diabetes.

  Journal of the Royal Society of Medicine 20020401

• [Postprandial hyperglycemia. II. Pharmacological approaches].

  Revue medicale de Liege 20020401

• Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20020401

• Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.

  Diabetes care 20020201

• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  JAMA 20020116

• Type 2 diabetes management.

  British journal of community nursing 20020101

• Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks.

  Pharmaceutical research 20020101

• The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.

  Journal of diabetes and its complications 20020101

• Type 2 diabetes management: a comprehensive clinical review of oral medications.

  Comprehensive therapy 20020101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020101

• Clinical pharmacokinetics and pharmacodynamics of repaglinide.

  Clinical pharmacokinetics 20020101

• Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line.

  Arzneimittel-Forschung 20020101

• Insulin secretagogues.

  Current medical research and opinion 20020101

• Preventing the progressive nature of type 2 diabetes.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20020101

• Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

  Clinical pharmacokinetics 20020101

• Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.

  Journal of postgraduate medicine 20020101

• Postprandial hyperglycemia in patients with type 2 diabetes mellitus.

  Treatments in endocrinology 20020101

• Insulinotropic meglitinide analogues.

  Lancet (London, England) 20011117

• The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.

  European journal of pharmacology 20011109

• Nateglinide therapy for type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20011101

• [Therapy of type 2 diabetes. Avoiding postprandial blood glucose peaks!].

  MMW Fortschritte der Medizin 20011004

• Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.

  Diabetes care 20011001

• Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.

  Diabetes care 20011001

• Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell.

  European journal of pharmacology 20010914

• Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.

  Current pharmaceutical design 20010901

• Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.

  Diabetes research and clinical practice 20010901

• [New drugs].

  Revue medicale de Bruxelles 20010901

• [News in oral antidiabetic therapy].

  Vnitrni lekarstvi 20010901

• [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].

  Nederlands tijdschrift voor geneeskunde 20010811

• Utilization of oral hypoglycemic agents in a drug-insured U.S. population.

  Diabetes care 20010801

• A new era in type 2 diabetes mellitus treatment?

  The American journal of medicine 20010701

• The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

  Clinical pharmacology and therapeutics 20010701

• [Objectives and therapeutic strategy in type 2 diabetes mellitus].

  Anales de medicina interna (Madrid, Spain : 1984) 20010701

• Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.

  Diabetologia 20010601

• [Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].

  Revue medicale de Liege 20010601

• [Repaglinide].

  Deutsche medizinische Wochenschrift (1946) 20010511

• Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.

  European journal of clinical pharmacology 20010501

• Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.

  Diabetic medicine : a journal of the British Diabetic Association 20010501

• Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions.

  Diabetes, obesity & metabolism 20010401

• [Large general practice study with repaglinide. Fewer 'anxiety eating' in diabetic patients].

  MMW Fortschritte der Medizin 20010308

• Repaglinide-induced factitious hypoglycemia.

  The Journal of clinical endocrinology and metabolism 20010201

• Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.

  Prescrire international 20010201

• Current understanding regarding the role of repaglinide in post-prandial hyperglycemia.

  The Journal of the Association of Physicians of India 20010125

• The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.

  The Journal of the Association of Physicians of India 20010125

• Combination therapy in type 2 diabetes: the role of repaglinide.

  The Journal of the Association of Physicians of India 20010125

• Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.

  Diabetes care 20010101

• Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.

  Diabetes care 20010101

• Honing type 2 diabetes treatment.

  Health news (Waltham, Mass.) 20010101

• Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101

• Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

  Drugs 20010101

• [New molecules].

  Journal de pharmacie de Belgique 20010101

• Patient perceptions of prandial oral therapy for type 2 diabetes.

  The Diabetes educator 20010101

• Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.

  International journal of experimental diabetes research 20010101

• Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas.

  International journal of experimental diabetes research 20010101

• Pharmacology and clinical experience with repaglinide.

  Expert opinion on investigational drugs 20000401